(Q46569123)

23 December 2017

title

Risk factors for early death in neonates with Down syndrome and transient leukaemia (English)

1 reference

23 December 2017

1 reference

1 reference

Hideki Muramatsu

1

1 reference

23 December 2017

Koji Kato

2

1 reference

23 December 2017

Nobuhiro Watanabe

3

1 reference

23 December 2017

Kimikazu Matsumoto

4

1 reference

23 December 2017

Tomohiko Nakamura

5

1 reference

23 December 2017

Yasuo Horikoshi

6

1 reference

23 December 2017

Junichi Mimaya

7

1 reference

23 December 2017

Chizuko Suzuki

8

1 reference

23 December 2017

Masahiro Hayakawa

9

1 reference

23 December 2017

Seiji Kojima

10

1 reference

23 December 2017

language of work or name

English

0 references

publication date

28 May 2008

1 reference

23 December 2017

British Journal of Haematology

published in

1 reference

23 December 2017

volume

142

1 reference

23 December 2017

issue

4

1 reference

23 December 2017

page(s)

610-615

1 reference

23 December 2017

Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07231.X

AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07231.X

Life-threatening complications of transient abnormal myelopoiesis in neonates with Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07231.X

Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07231.X

Transient abnormal myelopoiesis (TAM) causing multiple organ failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07231.X

An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07231.X

Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07231.X

A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07231.X

10.1111/J.1365-2141.2008.07231.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017